A Phase 2 interventional study of omiganan and placebo in Papulopustular Rosacea, sponsored by Maruho Co., Ltd.. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-20.
Sponsored by Maruho Co., Ltd. · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
231 studies on the registry are indexed under Rosacea; 20 are open to participants now.
This study's enrollment of 240 is above the median of 61 across 199 interventional studies indexed under Rosacea.
Browse Rosacea studies →Maruho Co., Ltd. is the lead sponsor of 27 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
omiganan mid dose once daily application for 12 weeks
Drug: omiganan
omiganan high dose once daily application for 12 weeks
Drug: omiganan
Vehicle once daily application for 12 weeks
Drug: placebo
omiganan low dose once daily application for 12 weeks
Drug: omiganan
Change in inflammatory lesion count
Time frame: 0, 1, 3, 6, 9 and 12 weeks
Success on IGA defined as clear or almost clear
Time frame: Week 12
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omiganan